MEDI-6469

N/A

Report date: 2022/08/12 16:11:07

Base Information

Drug NameMEDI-6469
Drug Alias NameMEDI-6469AGX-051
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionImmunomodulatorsTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesProvidence Cancer CenterAgonOx IncAstrazeneca Plc +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesMedimmune LlcProvidence Health & Services
Inactive CompaniesAgonOx IncLudwig Institute For Cancer Research
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A